CEL-SCI Corporation (CVM) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CEL-SCI Corporation on May 14, 2026, covering events occurring on May 11, 2026. The company is incorporated in Colorado and trades on the NYSE American under the symbol CVM.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a material definitive agreement rather than periodic financial results.
Material Changes and Agreements
On May 11, 2026, CEL-SCI entered into a strategic partnership, distribution, and revenue sharing agreement with Amarox. Key terms include:
- Product: Multikine (Leukocyte Interleukin, Injection) for the treatment of head and neck cancer.
- Scope: Regulatory affairs, marketing, and potential commercialization in Saudi Arabia.
- Expansion Option: An optional extension to cover Gulf Cooperation Council (GCC) countries, including Bahrain, Kuwait, Oman, Qatar, and the United Arab Emirates.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a detailed risk factor analysis beyond the standard disclosure of the new agreement. The primary focus is the execution of the partnership to advance commercialization efforts in the Middle East region.
Investor Verification Checklist
- Review the full text of the Agreement with Amarox (Exhibit 10) to understand specific revenue sharing percentages and milestone payments.
- Verify the regulatory status of Multikine in Saudi Arabia and the GCC countries to assess the timeline for commercialization.
- Confirm the financial impact of this partnership on future cash flows, noting that no immediate revenue figures were disclosed in this 8-K.
- Check subsequent press releases or filings for updates on the optional extension to other GCC nations.